Arrowhead

DESERT MOUNTAIN ENERGY ACQUIRES HELIUM-BEARING GAS FIELD IN NEW MEXICO

Retrieved on: 
Monday, June 19, 2023
Permian, Sin Nombre orthohantavirus, Compressibility, Cerro Pedernal, DME, Hydrogen, Wells, Sin Nombre, PSI, Record, Geology, NGL, Research, Movement, Arrowhead, Abo Formation, Acquisition, Water, BTU, Methane, Abo, Natural-gas condensate, Letter, Nitrogen, GPM, CO2, Butane, Propane, Pentane, Lithium, Natural gas, Silurian, Helium

The Company is pleased to announce that it has signed a binding letter of intent to purchase the Pecos Slope West Abo Gas Field and gas gathering system located in Chaves County, New Mexico.

Key Points: 
  • The Company is pleased to announce that it has signed a binding letter of intent to purchase the Pecos Slope West Abo Gas Field and gas gathering system located in Chaves County, New Mexico.
  • Generating additional revenue from Helium, CO2, methane credits and NGL's
    The Company plans to revitalize the Pecos Slope West Abo Gas Field and improve natural gas sales from the wells current level.
  • The Company's assessment, which began last year, includes an individual third-party gas analysis on 187 of the 188 gas wells.
  • The gas tests were conducted in February 2023 and show interesting gas composition dependent on the specific location within the Pecos Slope West Abo Gas Field.

Jostens and the Kansas City Chiefs Celebrate the Franchise’s Third Super Bowl Title with an Incredible Championship Ring that brings their 2022 Season to Life

Retrieved on: 
Friday, June 16, 2023
NFL, Bowl game, Partnership, Super Bowl ring, AFC, Super Bowl, Life, Kansas City Chiefs, Philadelphia Eagles, Trophy, Season, WORLD, Vince Lombardi Trophy, Milwaukee Chiefs (AFL), History, Organization, Dallas Texans, Philosophy, Championship ring, World championship, Collection, Super Bowl IV, Diamond, Pinnacle, Super Bowl LIV, Arrowhead Stadium, Arrowhead, AFL, Entertainment, Auction, Jewellery, Engraving, Kansas City metropolitan area, AFC West, Chief, Jostens

To commemorate this exciting chapter of Chiefs history, Jostens is proud to have crafted a Super Bowl Ring rich in storytelling and artful details that celebrate the Chiefs championship journey.

Key Points: 
  • To commemorate this exciting chapter of Chiefs history, Jostens is proud to have crafted a Super Bowl Ring rich in storytelling and artful details that celebrate the Chiefs championship journey.
  • The Kansas City Chiefs Super Bowl LVII Ring is not only filled with unique details, but it also boasts an impressive stone count.
  • To share the excitement of the Chiefs Super Bowl LVII victory, Jostens is proud to present Chiefs Kingdom with the official Super Bowl LVII Championship jewelry collection.
  • In addition to crafting the Kansas City Chiefs 2022 Super Bowl LVII Championship Ring, Jostens also created their 2019 Super Bowl LIV Championship Ring, 1969 Super Bowl IV Championship Ring, and the 2020 AFC Championship Ring.

Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences

Retrieved on: 
Tuesday, June 6, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Arrowhead, EASL, Goldman, Liver disease, Goldman Sachs, Congress, European Association for the Study of the Liver, Conference, Pharmaceutical industry, Dietary supplement, Liver

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
    Jefferies Global Healthcare Conference – June 8, 2023
    Goldman Sachs 44th Annual Global Healthcare Conference – June 12, 2023
    European Association for the Study of the Liver (EASL) Congress 2023 – June 24, 2023
    Title: Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study
    Webcast links and presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics

Retrieved on: 
Thursday, June 1, 2023
Research, Genetics, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, General Health, Science, Molecule, Arrowhead, Idiopathic pulmonary fibrosis, Asthma, Research and development, University, Therapy, Hypertriglyceridemia, File, Leonard M. Miller School of Medicine, Serum, CTA, Targeted molecular therapy for neuroblastoma, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., NYU Langone Health, CNS, Hepatocyte, University of Kansas Medical Center, Small RNA, SOD1, Arrowhead Pharmaceuticals, Patient, Primate, Fatty liver disease, Liver, RNA interference, ASCVD, Adipose tissue, Moyamoya disease, R, Goldberg, ALS, Gene, Medical device, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today beginning at 9:00 a.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today beginning at 9:00 a.m.
  • ET to discuss progress towards the company’s “20 in 25” goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiM™) platform to a total of 20 clinical stage or marketed products in the year 2025.
  • Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: “In 2017 we had optimized the TRiM™ platform for hepatocyte delivery, but we had yet to advance any candidates into clinical studies.
  • (University of Kansas Medical Center), who will discuss the muco-obstructive and inflammatory pulmonary disease landscape; and Ira Goldberg, M.D.

Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH

Retrieved on: 
Tuesday, May 23, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Arrowhead, Ezetimibe, Triglyceride, Cardiovascular disease, Lipid, ANGPTL3, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Trial of the century, Hypercholesterolemia, Glutamate-rich protein 3, Arrowhead Pharmaceuticals, Patient, LDL, PCSK9, RNA interference, Apolipoprotein B, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), in patients with homozygous familial hypercholesterolemia (HoFH).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), in patients with homozygous familial hypercholesterolemia (HoFH).
  • The company is currently planning a Phase 3 study to further investigate ARO-ANG3 and intends to conduct a meeting with regulatory authorities in the second half of 2023 to discuss the proposed study design.
  • The data were presented at the 91st European Atherosclerosis Society Congress in a poster titled, “ARO-ANG3, an Investigational RNAi Therapeutic, Decreases Serum LDL-Cholesterol, Apolipoprotein B, and Angiopoietin-like Protein 3 in Patients with Homozygous Familial Hypercholesterolaemia,” which may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
  • The data generated in the GATEWAY study of ARO-ANG3 in patients with HoFH and our prior clinical studies in patient populations with different levels and cause of hypercholesterolemia, demonstrate that ANGPTL3 inhibition led to substantial reductions in LDL-cholesterol, Non-HDL-C, triglycerides, ApoB, and other key lipids and atherogenic lipoproteins.

Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

Retrieved on: 
Tuesday, May 16, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Arrowhead, Trust, PALISADE, Arrowhead Pharmaceuticals, Patient, Dura Pharmaceuticals, Inc. v. Broudo, FCS, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of its global Phase 3 clinical trial (PALISADE) evaluating ARO-APOC3 for the treatment of familial chylomicronemia syndrome.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of its global Phase 3 clinical trial (PALISADE) evaluating ARO-APOC3 for the treatment of familial chylomicronemia syndrome.
  • The company anticipates that the primary portion of the study will be complete in the second quarter of 2024 with a data readout shortly thereafter and subsequent submissions for regulatory review and approval.
  • Javier San Martin, M.D., chief medical officer at Arrowhead, said: “Completing enrollment of the Phase 3 PALISADE study represents a significant milestone for Arrowhead and brings our potentially important RNAi-based medicines closer to the patients that may benefit from them.
  • I am grateful to the FCS patient community and principal investigators for their trust and participation in the PALISADE study.”

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

Retrieved on: 
Monday, May 15, 2023
Infectious Diseases, FDA, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Arrowhead, Congress, Conference, Democratic Society Congress

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:
    2023 RBC Capital Markets Global Healthcare Conference – May 17, 2023
    91st European Atherosclerosis Society Congress – May 23, 2023
    Webcast links and presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Aduro Clean Technologies Announces Engagement of Investor Relations Services Provider, Arrowhead Business and Investment Decisions

Retrieved on: 
Thursday, May 4, 2023
ACT, Arrowhead, Investment decisions, Plastic, CSE, FSE, Research, European Technology Platform on Smart Systems Integration, Oil, ESG

("Arrowhead") to provide investor relations services to the Company and develop its international market awareness.

Key Points: 
  • ("Arrowhead") to provide investor relations services to the Company and develop its international market awareness.
  • Arrowhead advises public companies on investor relations, financial communications, and capital markets strategies.
  • Daniel Renaud, Managing Director at Arrowhead added: “We are thrilled by this engagement to represent Aduro Clean Technologies and raise investor awareness of this mission driven company.
  • We believe many market participants will find the information we provide on Aduro valuable and will take interest in their business.”

Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results

Retrieved on: 
Tuesday, May 2, 2023
Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Molecule, SEQUOIA, Arrowhead, Volunteering, GSK, Idiopathic pulmonary fibrosis, Asthma, Central nervous system, NASH, Takeda, Triglyceride, Clinical trial, Folate targeting, Brain, Research, Part, CNS, Trial of the century, PIN, Outline, Patient, PNPLA3, Fatty liver disease, Webcast, RNA interference, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Janssen Pharmaceuticals, Food, Pharmaceutical industry, Vaccine, C3

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023.
  • The company is hosting a conference call today, May 2, 2023, at 4:30 p.m.
  • Reported interim results from an ongoing Phase 1/2 clinical study of ARO-RAGE, an investigational RNAi therapeutic for treatment for inflammatory pulmonary diseases, such as asthma.
  • Key results from Part 1 of the study in normal healthy volunteers included the following:
    These results include 4 of 5 escalating dose levels.

Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect

Retrieved on: 
Tuesday, April 25, 2023
Health, Hospitals, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Molecule, Arrowhead, Interim, Critical care, RAGE, Asthma, University, Folate targeting, University of Kansas Health System, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., RNA, Trial of the century, Arrowhead Pharmaceuticals, Patient, University of Kansas Medical Center, RNA interference, Research, Safety, Pharmaceutical industry

These data represent the first clinical demonstration of the potential utility of Arrowhead’s proprietary Targeted RNAi Molecule (TRiMTM) platform optimized for delivery to the lungs.

Key Points: 
  • These data represent the first clinical demonstration of the potential utility of Arrowhead’s proprietary Targeted RNAi Molecule (TRiMTM) platform optimized for delivery to the lungs.
  • Matthias Salathe, M.D., Professor, Pulmonary, Critical Care and Sleep Medicine, and Vice Chancellor for Research at the University of Kansas Medical Center, said: “These interim ARO-RAGE Phase 1/2 data are highly encouraging.
  • Unmet need continues to exist for many patients with severe asthma who suffer from persistent symptoms and exacerbations, despite current therapies.
  • The high level of target gene knockdown, the long duration of effect, and the promising safety and tolerability results are all very encouraging signs for our growing pipeline of RNAi therapeutic candidates that leverage this same platform.